Agios Pharmaceuticals Inc (AGIO): Insights At A Glance

Agios Pharmaceuticals Inc (AGIO) concluded trading on Thursday at a closing price of $29.24, with 0.43 million shares of worth about $12.71 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 19.18% during that period and on March 28, 2024 the price saw a gain of about 0.41%. Currently the company’s common shares owned by public are about 55.95M shares, out of which, 54.74M shares are available for trading.

However, the stock later moved at a day high price of 29.42, or with a gain of 0.41%. Stock saw a price change of -3.31% in past 5 days and over the past one month there was a price change of -13.16%. Year-to-date (YTD), AGIO shares are showing a performance of 31.30% which increased to 29.67% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $19.80 but also hit the highest price of $35.50 during that period. The average intraday trading volume for Agios Pharmaceuticals Inc shares is 847.89K. The stock is currently trading -4.23% below its 20-day simple moving average (SMA20), while that difference is up 6.59% for SMA50 and it goes to 15.57% higher than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Agios Pharmaceuticals Inc (NASDAQ: AGIO) currently have 55.95M outstanding shares and institutions hold larger chunk of about 107.20% of that.

The stock has a current market capitalization of $1.64B and its 3Y-monthly beta is at 0.82. It has posted earnings per share of -$6.33 in the same period. It has Quick Ratio of 11.99 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AGIO, volatility over the week remained 3.01% while standing at 3.58% over the month.

Analysts are in expectations that Agios Pharmaceuticals Inc (AGIO) stock would likely to be making an EPS of -$1.64 in the current quarter, while forecast for next quarter EPS is -$1.66 and it is -$5.87 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.78 which is -$1.48 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.47 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -5.19% while it is estimated to increase by 11.81% in next year. EPS is likely to grow at an annualized rate of 39.00% for next 5-years, compared to annual growth of -0.98% made by the stock over the past 5-years.

Coverage by Piper Sandler stated Agios Pharmaceuticals Inc (AGIO) stock as an Overweight in their note to investors on February 03, 2023, suggesting a price target of $41 for the stock. On November 17, 2022, Goldman Upgrade their recommendations, while on July 27, 2022, SVB Leerink Upgrade their ratings for the stock with a price target of $33. Stock get a Buy rating from BofA Securities on December 03, 2021.

Most Popular

Related Posts